LDS/Medical Tests/Thyroid GuidePx® for Papillary Thyroid Cancer

Thyroid GuidePx® for Papillary Thyroid Cancer

Papillary thyroid carcinoma (PTC) arises from follicular epithelial cells of the thyroid gland and accounts for approximately 80–85% of all thyroid malignancies. Although PTC often has an excellent overall prognosis, recurrence is relatively common, and lymphatic spread can occur early.

The Thyroid GuidePx® is a molecular prognostic tool based on next-generation RNA sequencing (NGS) of 82 PTC-associated genes. It identifies a personalized mutational signature, classifying patients into low, intermediate, or high-risk categories based on molecular subtypes. This risk stratification aids in prognosis and personalized treatment planning. The test has been clinically validated to distinguish more aggressive forms of PTC and predict the likelihood of disease recurrence, guiding intensity of surveillance and therapeutic approaches.

  • Assists in risk stratification of papillary thyroid carcinoma patients based on tumor molecular profile
  • Aids in predicting recurrence risk post-surgery and decision-making regarding adjuvant therapy (e.g., radioactive iodine) and frequency of surveillance

Patients are categorized into one of three molecular subtypes (Type 1, 2, or 3).

  • Subtypes 2 and 3, especially with tumor size >4 mm, are associated with higher risk of recurrence, persistent disease, and advanced pathological features.
  • Interpretation should be integrated with other clinicopathologic data, including tumor size, extrathyroidal extension, lymph node status, and histology.
  • A low-risk molecular signature may suggest consideration for less aggressive treatment and follow-up.
Subtype Risk Category Clinical Implications
Type 1 Low Risk Standard surveillance; excellent prognosis
Type 2 Intermediate Risk Closer follow-up; consider adjuvant therapy
Type 3 High Risk Aggressive management; intensive surveillance

Not applicable (qualitative risk classification based on molecular subtype)

Targeted RNA sequencing (next-generation sequencing, NGS). Analyzes expression of 82 target genes and 10 housekeeping genes.

Whole blood, EDTA.

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
Biochemical Markers: TSH, free T4, total T3, Molecular Markers: BRAF V600E mutation analysis, RET/PTC rearrangements (if clinically indicated), Parathyroid Hormone (iPTH): If parathyroid involvement suspected.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Surgery. 2025 Jan:177:108882. [PMID: 39490256]
  • Int J Med Sci. 2019 Feb 28;16(3):450-460. [PMID: 30911279]
  • Oncotarget. 2017 Feb 7;8(6):10637-10649. [PMID: 27793009]
  • Qualisure Diagnostics. Thyroid GuidePx® for Papillary Thyroid Cancer. Website
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login